drugset / Trial / NCT05361369

Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

NCT05361369

Phase 1 Completed 18 enrolled Exeltis Turkey MonitorCRO · collab
NaSingle-groupOpen-labelOther

Summary

A single dose of the study drug will be administered to healthy female subjects in a single period to obtain pharmacokinetic parameters for each active ingredient.

Timeline

Start
2022-05-09
Primary completion
2022-05-13
Completion
2023-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 100 mg Other
Subject fenticonazole Small molecule 600 mg Other
Subject tinidazole Small molecule 1000 mg Other

Indications

No indication recorded.